Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
Ginkgo Bioworks Holdings, Inc. director and officer Reshma P. Shetty, reporting indirect holdings "by spouse," disclosed PSU vesting and related share sales. On April 7–8, 2026, her spouse exercised 55,476 performance-based restricted stock units at $0.00 per unit into Class A Common Stock.
On April 8 and 9, 2026, a total of 26,271 Class A shares were sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations tied to the PSU vesting, which the footnotes state were not discretionary trades. After these transactions, the spouse’s indirect Class A Common Stock holdings were 338,568 shares.
Ginkgo Bioworks Holdings, Inc. 10% owner Barry Canton reported compensation-related stock activity tied to performance-based restricted stock units (PSUs). On April 7 and 8, 2026, he exercised 55,476 PSUs at $0.00 per unit, receiving the same number of Class A Common shares.
According to the disclosure, 26,271 Class A shares were then sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations upon PSU vesting. The filing notes these “sell to cover” trades are not discretionary. After these transactions, Canton directly held 338,568 Class A Common shares.
The PSUs stem from an 82,800-unit grant made on June 19, 2025, based on a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025. The total PSUs vested reflect performance at 67% of target, as certified by the board’s Compensation Committee.
Ginkgo Bioworks Holdings director and officer Jason R. Kelly reported PSU vesting and related share sales. On April 7 and 8, 2026, he exercised performance-based restricted stock units to receive a total of 425,898 shares of Class A Common Stock at a conversion price of $0.0000 per share.
Footnotes state that 206,782 of these shares were sold at prices of about $6.93 and $6.397 per share solely to cover tax withholding obligations in connection with the PSU vesting, under the company’s “sell to cover” provisions, and are not discretionary trades. After these transactions, he directly held 316,483 Class A shares.
The PSUs were part of a 635,670-unit grant dated June 19, 2025, tied to a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025, with actual performance certified at 67% and shares distributed on April 7 and 8, 2026.
Filer reported sales of restricted Class A shares. The filing lists two recent dispositions by Bartholomew Canton: 13,155 shares on 04/08/2026 and 13,116 shares on 04/09/2026, with dollar amounts shown. The record also lists 124,727 shares associated with Fidelity Brokerage Services LLC and a total share figure of 49,941,878 as of 04/10/2026.
Issuer reported a Form 144 notice for the proposed sale of 13,116 Class A shares under Rule 144. The shares arose from Restricted Stock Vesting dated 04/08/2026 and are held at Fidelity Brokerage Services LLC.
The filing lists prior sales of 13,155 Class A shares by Bartholomew Canton on 04/08/2026 and shows 49,941,878 shares outstanding as of 04/09/2026.
Jason Kelly reports a proposed sale of 109,767 shares of Class A common stock under Form 144. The securities are tied to restricted stock vesting as compensation and dated 04/08/2026. The filing shows 97,015 shares sold during the past three months, with values listed as $702,201.45 and $672,343.05. Trades are noted for the NYSE and the filing header date is 04/09/2026.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.
Ginkgo Bioworks Holdings Inc: The Vanguard Group filed an Amendment No. 5 to its Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of Ginkgo Bioworks common stock. The filing explains an internal realignment effective 01/12/2026 that disaggregated certain Vanguard subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries under SEC Release No. 34-39538.